Application of a preparation of imiquimod in а dosage form of ointment 5% in therapy of basal cell carcinoma

Cover Page
  • Authors: Zaslavsky D.V.1, Chuprov I.N.2, Sidikov A.A.1, Wolkensteyn P.3, Sadykov A.I.4, Sibgatullin R.R.5, Koval Y.G.6, Skrek S.V.2,6
  • Affiliations:
    1. Saint-Petersburg state pediatric medical university
    2. North-West state medical university of I.I. Mechnikov
    3. Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor
    4. Medical centre XXI vek
    5. Leningrad regional oncological clinic
    6. Clinic of skin diseases of Pierre Wolkenstein
  • Issue: Vol 91, No 6 (2015)
  • Pages: 67-74
  • Section: GUIDELINES FOR PRACTITIONERS
  • URL: https://www.vestnikdv.ru/jour/article/view/200
  • DOI: https://doi.org/10.25208/0042-4609-2015-91-6-67-74

Abstract


Objective. To estimate efficiency and safety of application of a preparation of Aldara (imiquimod, 5% external application cream) it is independent or in combination with cryotherapy in therapy of the basal cell carcinoma of the skin (BCC). Material and methods. Research included 78 patients (22 women and 56 men) with various forms of a basal cell carcinoma of the skin. All patients were divided into 3 groups: the main group (n = 30) the patients receiving therapy by Aldara (imiquimod, 5% external application cream) made, second (n = 21) - the patients receiving therapy by Aldara’s, and also 1 course of cryotherapy, and the group of comparison (n = 27) receiving therapy of placebo in the form of external application cream. Therapy was carried out 3 times a week, within 16 weeks. Research was conducted in some stages with histologic confirmation of the diagnosis, and also an assessment of efficiency of therapy and undesirable effects. Results. At 27 of 30 patients of the first group (90%) and at 21 of 21 patients of the second group (100%) receiving treatment by Aldara’s absolute clinical recovery is reached. In group of comparison of clinical recovery at all 27 patients it wasn’t observed. It is expedient to note that at all patients of the second group (100%) already to 75 ± to the 2nd day of therapy (the 4th visit) clinical recovery while at 27 of 30 patients of the first group (90%) the total disappearance (clinical recovery) came for 105 and more days (the 5th and 6th visits) was noted. Recurrence of a disease after the end of therapy it wasn’t observed. Conclusion. Aldara (imiquimod, 5% external application cream) possesses high efficiency at therapy of various forms and sizes of BCC. Undesirable effects of therapy are easily resolved at cancellation of a preparation and not observed at its renewal. Unlike other immunomodulatory preparations (corticosteroids, retinoid, cyclosporin) Aldar’s application doesn’t promote suppression of cellular immunity.

D. V. Zaslavsky

Saint-Petersburg state pediatric medical university

Author for correspondence.
Email: venerology@gmail.com

Russian Federation

I. N. Chuprov

North-West state medical university of I.I. Mechnikov

Email: venerology@gmail.com

Russian Federation

A. A. Sidikov

Saint-Petersburg state pediatric medical university

Email: venerology@gmail.com

Russian Federation

PIER Wolkensteyn

Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor

Email: venerology@gmail.com

Russian Federation

A. I. Sadykov

Medical centre XXI vek

Email: venerology@gmail.com

Russian Federation

R. R. Sibgatullin

Leningrad regional oncological clinic

Email: venerology@gmail.com

Russian Federation

Y. G. Koval

Clinic of skin diseases of Pierre Wolkenstein

Email: venerology@gmail.com

Russian Federation

S. V. Skrek

North-West state medical university of I.I. Mechnikov; Clinic of skin diseases of Pierre Wolkenstein

Email: venerology@gmail.com

Russian Federation

  1. Дерматоонкология. Под ред. Галил-Оглы Г.А., Молочкова В.А., Сергеева Ю.В. М.: Медицина для всех. 2005. 872
  2. Bath-Hextall F. et al. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007; 9: 2105-2108
  3. Roewert-Huber J. et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 2007. № 6, Suppl 2. P. 47-51
  4. LeSueur B.W. Basal cell carcinoma in children: report of 3 cases / LeSueur B.W., Silvis N.G., Hansen R.C. Arch Dermatol. 2000; 3: 370-372
  5. Estrada J.G. Non-melanoma skin cancer in Catalonia. A community-based prevalence study / J.G. Estrada. Int J Dermatol. 2005; 11: 922-924
  6. Al-Maghrabi J.A. Pattern of skin cancer in Southwestern Saudi Arabia / Al-Maghrabi J.A., Al-Ghamdi A.S., Elhakeem H.A. Saudi Med J 2004; 6: 776-779
  7. Saari K.M. et al. Epidemiology of basal cell carcinoma of the eyelid in south-western Finland Graefes Arch Clin Exp Ophthalmol. 2001; 3: 230-233.
  8. MacKie R.M. Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe / MacKie R.M. J Eur Acad Dermatol Venereol 2004; 5: 552-555.
  9. Дубенский, В.В. Современные аспекты эпидемиологии, патогенеза, клиники и лечения базально-клеточного кожи. Дубенский В.В., Гармонов А.А. Вестн дерматол венерол 2004; (6): 7-12
  10. Кулагин В.И. Заболеваемость базальноклеточным и плоскоклеточным раком кожи среди жителей Москвы / Кулагин В.И., Сдвижков А.М., Умеренков М.Г. Росс журн кож вен бол 2001; (6): 4-6
  11. Приходько С.Г. Метатипический рак кожи. Приходько С.Г., Мартынюк В.В., Иржанов С.И. Вестн дерматол венерол 1986; (7): 62-63
  12. Kikuchi A. Clinical histopathological characteristics of basal cell carcinoma in Japanese patients. A. Kikuchi, H. Shimizu, T. Nishikawa. Arch Dermatol 1996; 3: 320-324
  13. Снарская Е.С., Базалиома. Снарская Е.С., Молочков В.А. М: Медицина 2003. 324
  14. Betti R. et al. Basal cell carcinoma of the sole. J Dermatol 2005; 6: 50-53
  15. Кубанова А.А., Кубанов А.А., Заславский Д.В. и др. Ведение больных с ИПППиурогенитальными инфекциями (клинические рекомендации). М: ДЭКС-ПРЕСС. 2012. 13
  16. Liota E., Smith K.J., Buckley R., Menon P., Skelton H. Imiquimod therapy for molluskum contagiosum. J Cutan Med Surg. 2000; 4: 76-82
  17. Dytoc M., Wat H., Cheung-Lee M., Sawyer D., Ackerman T., Fiorillo L. Evaluation of the Efficacy and Safety of Topical Imiquimod 5% for Plaque-Type Morphea: A Multicenter, Prospective, Vehicle-Controlled Trial. J Cutan Med Surg. 2015; Mar 11. pii: 7750.2014.14072
  18. Mackenzie-Wood A., Kossard S., De Launey J., Wilkinson B. Owens Ml. J Am Acad Dermatol. Imiquimod 5% cream in the treatment of Bowen's disease. 2001; 44: 462-470
  19. Sauder D.N. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000; 43: 6-11.
  20. Gibson S., Lind J., Riter T. et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cellular Immunol 2002; 218 (1-2): 74-86.
  21. Wang B., Shivji G.M. et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.

Views

Abstract - 84

PDF (Russian) - 85

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies